PCSK9 Forum is made possible thanks to support from AstraZeneca, Lib Therapeutics, Novartis and Sanofi, all of whom have no influence or control of editorial content. More information is available here »

Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS

Latest News Updates

Targeting PCSK9 and ANGPTL3 with statin regresses atherosclerosis

Posted on 29 January 2020 | Posted in News

In a mouse model of hyperlipidaemia, the combination of the PCSK9 inhibitor alirocumab, a monoclonal antibody to ANGPTL3 (angiopoietin-like 3 protein) evinacumab, and atorvastatin not only reduced LDL cholesterol by 73% but also regressed atherosclerosis.

Read the article: Pouwer MG, et al. Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. J Lipid Res 2019; doi: 10.1194/jlr.RA119000419. [Epub ahead of print] PUBMED https://www.ncbi.nlm.nih.gov/pubmed/31843957

Read the accompanying editorial: Hurt-Camejo E. Combination ANGPTL3, PCSK9 and statin therapy drives remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model. J Lipid Res 2020;doi: 10.1194/jlr.C120000650. [Epub ahead of print]

PUBMED https://www.ncbi.nlm.nih.gov/pubmed/31980481

Related content

Evinacumab, ANGPTL3 inhibitor, awarded breakthrough status by FDA

EAS Congress Innsbruck: Mixed results with novel agents in homozygous FH

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved